Anca Bulgaru, MD
she/her/hers
Assistant Professor of Medicine (Medical Oncology)
Research & Publications
Biography
News
Selected Publications
- Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumorsGoel S, Bauer R, Desai K, Bulgaru A, Iqbal T, Strachan B, Kim G, Kaubisch A, Vanhove G, Goldberg G, Mani S. Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Annals Of Oncology 2007, 18: 1704-1707. PMID: 17693421, DOI: 10.1093/annonc/mdm280.
- PO-50 Management practices of Connecticut physicians for treatment of cancer patients with venous thrombosisDhami R, Bulgaru A, Jagathambal K, Johnson S, Kapur D, Slater D, Dhami M. PO-50 Management practices of Connecticut physicians for treatment of cancer patients with venous thrombosis. Thrombosis Research 2007, 120: s161. DOI: 10.1016/s0049-3848(07)70203-7.
- Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancersGoel S, Desai K, Karri S, Gollamudi R, Chaudhary I, Bulgaru A, Kaubisch A, Goldberg G, Einstein M, Camacho F, Baker S, Mani S. Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. Investigational New Drugs 2006, 25: 237-245. PMID: 17195945, DOI: 10.1007/s10637-006-9028-1.
- Treatment of Acute Myeloid Leukemia in a Community Hospital.Dhami M, Bulgaru A, Jagathambal K, Kapur D, Slater D, Maderazo E, Bauer F. Treatment of Acute Myeloid Leukemia in a Community Hospital. Blood 2006, 108: 4575. DOI: 10.1182/blood.v108.11.4575.4575.
- Use of Venipuncture Blood Sample for INR Testing on a Point of Care Machine.Dhami M, Bulgaru A, Jagathambal K, Kapur D, Norris F, Slater D, Cavanaugh J. Use of Venipuncture Blood Sample for INR Testing on a Point of Care Machine. Blood 2005, 106: 4159. DOI: 10.1182/blood.v106.11.4159.4159.
- Single Institution Experience with Inferior Vena Cava Filters.Bhalla N, Bulgaru A, Church L, Kapur D, Lustberg H, Slater D, Dhami M. Single Institution Experience with Inferior Vena Cava Filters. Blood 2005, 106: 914. DOI: 10.1182/blood.v106.11.914.914.
- Phase I and pharmacokinetic study of a subcutaneously administered human-engineered monoclonal antibody ING-1 in patients with advanced adenocarcinomasKiner-Strachan B, Goel S, Vanhove G, Bauer R, Verdier-Pinard D, Karri S, Desai K, Bulgaru A, Macapinlac M, Mani S. Phase I and pharmacokinetic study of a subcutaneously administered human-engineered monoclonal antibody ING-1 in patients with advanced adenocarcinomas. Journal Of Clinical Oncology 2005, 23: 2558-2558. DOI: 10.1200/jco.2005.23.16_suppl.2558.
- A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignanciesFriedman D, Goel S, Desai K, Verdier-Pinard D, Kaubisch A, Bulgaru A, Camacho F, Goldberg G, Mani S. A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies. Journal Of Clinical Oncology 2004, 22: 2113-2113. DOI: 10.1200/jco.2004.22.14_suppl.2113.
- A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignanciesFriedman D, Goel S, Desai K, Verdier-Pinard D, Kaubisch A, Bulgaru A, Camacho F, Goldberg G, Mani S. A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies. Journal Of Clinical Oncology 2004, 22: 2113-2113. DOI: 10.1200/jco.2004.22.90140.2113.
- Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumorsGoel S, Bulgaru A, Hochster H, Wadler S, Zamboni W, Egorin M, Ivy P, Leibes L, Muggia F, Lockwood G, Harvey E, Renshaw G, Mani S. Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors. Annals Of Oncology 2003, 14: 1682-1687. PMID: 14581279, DOI: 10.1093/annonc/mdg453.
- A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors.Goel S, Desai K, Bulgaru A, Fields A, Goldberg G, Agrawal S, Martin R, Grindel M, Mani S. A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clinical Cancer Research 2003, 9: 4069-76. PMID: 14519628.
- The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics.Liu W, Bulgaru A, Haigentz M, Stein CA, Perez-Soler R, Mani S. The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics. Anti-Cancer Agents In Medicinal Chemistry 2003, 3: 217-23. PMID: 12769779, DOI: 10.2174/1568011033482459.